EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK

被引:0
|
作者
Rafia, R. [1 ]
Papaioannou, D. [1 ]
Stevenson, M. [1 ]
Rathbone, J. [1 ]
Woods, H. B. [1 ]
机构
[1] Univ Sheffield, Sheffield, S Yorkshire, England
关键词
D O I
10.1016/j.jval.2011.08.1165
中图分类号
F [经济];
学科分类号
02 ;
摘要
引用
收藏
页码:A445 / A445
页数:1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
  • [2] An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
    Ray, Joshua A.
    Carr, Emma
    Lewis, Gavin
    Marcus, Robert
    VALUE IN HEALTH, 2010, 13 (04) : 346 - 357
  • [3] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [4] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [5] Cost-effectiveness of rituximab in follicular lymphoma
    Johnston, Karissa M.
    Bolbocean, Corneliu
    Connors, Joseph
    Peacock, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 569 - 577
  • [6] COST-EFFECTIVENESS ANALYSIS OF MAINTENANCE TREATMENT WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA RESPONDING TO FIRST LINE INDUCTION THERAPY IN PORTUGAL
    Pereira, C.
    Rubio Terres, C.
    Rubio Rodriguez, D.
    VALUE IN HEALTH, 2014, 17 (07) : A530 - A531
  • [7] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [8] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [9] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
    Kasteng, Frida
    Erlanson, Martin
    Hagberg, Hans
    Kimby, Eva
    Relander, Thomas
    Lundkvist, Jonas
    ACTA ONCOLOGICA, 2008, 47 (06) : 1029 - 1036
  • [10] COST-EFFECTIVENESS OF RITUXIMAB IN FOLLICULAR LYMPHOMA FIRST LINE MAINTENANCE TREATMENT FROM PUBLIC PAYER PERSPECTIVE IN POLAND
    Gadaj, A.
    Kalinowska, A.
    Hawrylecka, D.
    Holojda, J.
    Krawcewicz, A.
    Spychalowicz, W.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A450